Sterne Kessler Obtains Settlement for Dexcel Pharma

Washington, D.C. (April 29, 2026) – Sterne, Kessler, Goldstein & Fox represented client Dexcel Pharma in connection with a settlement agreement resolving patent litigation brought by Pfizer Inc.

The litigation, filed in the U.S. District Court for the District of Delaware, involved patents relating to VYNDAMAX® (tafamidis), a treatment for transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM).

On Friday, April 24, 2026, the parties agreed to dismiss the case before bench trial was scheduled to begin.

The Sterne Kessler team representing Dexcel Pharma includes directors Dennies Varughese, Pharm.D., Christopher Gallo, Ph.D., and Gaby Longsworth, Ph.D.; counsel Tyler Liu; and associate Alexander Alfano.

Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs.

Read Law360’s coverage of the case.

About Sterne, Kessler, Goldstein & Fox
Based in Washington, D.C. and renowned for more than four decades for dedication to the protection, enhancement, and enforcement of intellectual property rights, Sterne, Kessler, Goldstein & Fox is one of the most highly regarded intellectual property specialty law firms in the world. Its team of attorneys, registered patent agents, technical specialists, specialized trademark paralegals, and law clerks include some of the country’s most respected practitioners of IP law, tackling innovations across a broad spectrum of industries. The firm’s practitioners represent Fortune 500 companies, entrepreneurs, start-ups, inventors, venture capital firms, and universities in a client service driven environment that is welcoming, inclusive, and intellectually stimulating. Visit the firm online at sternekessler.com.